| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2136be309d6c44157ddbe6d7ee2defc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-868 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-245 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
1996-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e7ba3d2250e17e5a74a7fd95490f1bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c930460b630c9ac0511888b806af64d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17d886a416d56cbf8b1c2da631024bdd |
| publicationDate |
2007-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CZ-298670-B6 |
| titleOfInvention |
The use of a medicament for the manufacture of a medicament for the prevention and / or treatment of autoimmune disease or human T cell leukemia or implant rejection, a pharmaceutical composition and a kit comprising the composition |
| abstract |
The use of a medicament for the manufacture of a medicament for the prevention and / or treatment of autoimmune disease or human T cell leukemia, wherein (i) the agent is EtxB (heat labile enterotoxin from E. coli, B subunit) and / or CtxB (cholera toxin, B subunit), not containing A subunit; (ii) if the agent is to be administered together with the antigenic determinant, then the agent and the antigenic determinant are not linked to form a single active agent. Also within the scope of the invention is a pharmaceutical composition comprising the agent and the kit. Another aspect is the use of a medicament for the manufacture of a medicament for the prevention and / or treatment of implant rejection or GVHD, wherein (i) the agent is EtxB (heat-labile enterotoxin from E. coli, subunit B), not containing subunit A; (ii) if the agent is to be administered together with the antigenic determinant, then the agent and the antigenic determinant are not linked to form a single active agent; and a pharmaceutical composition comprising the agent. |
| priorityDate |
1995-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |